Bayer Back Ada Health in $90M Round
May 27, 2021
Leaps by Bayer has led a USD 90 million Series B investment in
Berlin-based digital health company Ada Health GmbH ("Ada"). Additional
investors joined the round, including Samsung Catalyst Fund, Vitruvian
Partners, Inteligo Bank, F4 and Mutschler Ventures.
The investment will help advance Ada's popular health assessment
technology, enabling the digital health pioneer to accelerate its path
towards becoming the world's leading personalized operating system for
health, as well as to further grow the company's leading position in the
United States. In addition to today's announcement, Bayer and Ada Health
are in discussions about entering into a longer-term strategic
partnership to support the company's healthcare businesses.
Ada Health has developed a powerful AI-based health assessment and care
navigation platform that helps users to understand their symptoms, to
identify and differentiate conditions with a high degree of medical
accuracy, and to navigate safely to the right care, at the right time.
Ada's consumer app has become the world's most popular and highest-rated
symptom assessment app, with over 23 million assessments completed since
its global launch.
Ada's core technology is also available in a suite of AI-driven
enterprise solutions. The company is collaborating with a range of
leading health systems, insurers, life sciences companies, and global
non-profit organizations to integrate its symptom assessment and care
navigation solutions into a range of digital care journeys to improve
outcomes for patients, consumers and healthcare providers.
"Investing in breakthrough technologies that drive digital change in
healthcare is one of the strategic imperatives for Leaps by Bayer and
for the entire field of healthcare," said Dr. Jürgen Eckhardt, Head of
Leaps by Bayer. "Ada's truly transformative technology, combining
powerful artificial intelligence with an emphasis on medical rigor and
high levels of clinical accuracy will lead the way in helping more
patients and consumers in achieving better health outcomes sooner by
intervening earlier in their healthcare journey."
timely detection of diseases is one of the biggest challenges in guiding
consumers and patients to appropriate care, with under-diagnosis,
misdiagnosis, and long patient journeys to diagnosis and care
unfortunately being commonplace. In addition, global healthcare systems
are overburdened, with organizations required to meet pressures such as
growing and ageing populations, emerging comorbidity requiring
treatment, and the ongoing pandemic. Ada can help shorten time to
diagnosis by providing medical guidance that is relevant, actionable and
effective, and will increasingly leverage personalized data insights to
support the prediction and prevention of diseases.
"Today's investment will help bring us closer to our goal of improving
healthcare outcomes for more than 1 billion people around the world.
We're proud to have investors on board who truly believe in Ada's
technology and vision of transforming the way people access healthcare,"
Daniel Nathrath, CEO and co-founder of Ada Health comments on today's
announcement. "We are thrilled to have Leaps by Bayer as the lead
investor particularly as our values are very much aligned with putting
science and technology as well as a commitment to medical quality and
user-centricity at the heart of everything we do."